The short version of BDNF fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-24 and is reviewed periodically as new material appears.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | Reversed-phase HPLC with UV detection | Separates target peptide from truncated and oxidised forms |
| Identity confirmation | LC-MS or ESI-MS | Compares observed and calculated molecular ion |
| Primary degradation route | Methionine oxidation | Forms the sulfoxide; monitored as an early-eluting peak |
| Short-term storage | 2 to 8 degrees Celsius | Applies to working vials and reconstituted portions |
| Common synonyms | ACTH(4–10) analogue, MEHFPGP | Descriptive names used in laboratory catalogues |
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Nejnezdevětadevadesáteroroznásobovávatelnějšími (47; Instrumental case of the ones least multipliable by a group of ninety-nine on a regular basis) Nejnezdevětadevadesáteroroznásobovávatelnější (Those who are the least multiplable by a group ninety-nine on a regular basis) Nejzdevětadevadesáteroroznásobovávatelnější (Those who are the most multiplable by a group ninety-nine on a regular basis) Zdevětadevadesáteroroznásobovávatelnější (Those who are more multiplable by a group ninety-nine on a regular basis) Zdevětadevadesáteroroznásobovávatelní (Those who are multiplable by a group of ninety-nine on a regular basis) Zdevětadevadesáteroroznásobovávat (Alternative of "multiply out by a group of ninety-nine on a regular basis") Zdevětadevadesáteroroznásobovat (Multiply out by a group of ninety-nine on a regular basis — continuous grammatical aspect) Zdevětadevadesáteroznásobovat (Multiply by ninety-nine on a regular basis – continuous grammatical aspect) Zdevětadevadesáteroznásobit (Multiply by a group of ninety-nine once) Zdevětadevadesáteronásobit (Multiply by a group of ninety-nine) Devětadevadesátero (A group of ninety-nine) Devětadevadesát (Inverse of devadesát devět = ninety-nine)
Toxicology and pharmacology mainly concern the effects of a substance on a multi-cellular lifeform, usually an animal. As a result, anything that is not in vivo is in vitro. This includes animal organ cultures, animal tissue cultures (ex vivo), animal cell cultures, prokaryotic cell cultures, and isolated biomolecules. The study of pathogens treats the pathogen-in-host state as in vivo. (For example, the in vivo transcriptomics of E. coli during a urinary tract infection.) Accordingly, in vitro includes models that do not involve the entire host. Viruses, which only replicate in living cells, are studied in the laboratory in cell or tissue culture, and many animal virologists refer to such work as being in vitro to distinguish it from in vivo work in whole animals. The study of the molecular machineries tends to see the whole cell as the biggest unit. As a result, cell cultures (even mammalian ones) can be considered in vivo instead of the usual assignment as in vitro. In this context, in vitro exclusively refers to cell-free systems.
=== Available forms === Psilocybin is most commonly consumed in the form of psilocybin-containing mushrooms, such as Psilocybe species like Psilocybe cubensis. It may also be prepared synthetically, but outside of research settings it is not typically used in this form. Regardless of form, psilocybin is usually taken orally. The psilocybin present in certain species of mushrooms can be ingested in several ways: by consuming fresh or dried fruit bodies, by preparing an herbal tea, or by combining with other foods to mask the bitter taste. In rare cases people have intravenously injected mushroom extracts, with serious medical complications such as systemic mycological infection and hospitalization. Another form of psilocybin (as well as of related psychedelics like 4-AcO-DMT) is mushroom edibles such as chocolate bars and gummies, which may be purchased at psychedelic mushroom stores.
Court docket: United States v. Carvajal-Barrios (S.D.N.Y.), 1:11-cr-00205; second superseding indictment against Maduro and others "Crisis in Venezuela". Frontline. Season 44. Episode 9. 10 February 2026. PBS. WGBH. Retrieved 25 February 2026.
Sources: en.wikipedia.org
The transaction moves to the due diligence phase, where the buyer makes a more detailed assessment of the property. Purchase and sale agreements will generally include clauses which require the seller to disclose certain information for buyer's review to determine if the terms of the agreement are still acceptable. The buyer may have the right to terminate the transaction and/or renegotiate the terms, often referred to as "contingencies". Many purchase agreements are contingent on the buyer's ability to obtain mortgage financing and buyer's satisfactory review of specific due diligence items. Common due diligence items include property financial statements, rent rolls, vendor contracts, zoning and legal uses, physical and environmental condition, traffic patterns and other relevant information to the buyer's purchase decision specified in the PSA. In competitive real estate markets, buyers may waive contingencies in order to make an offer more appealing to a buyer. The PSA will usually require the seller to provide due diligence information to the seller in a timely manner and limit the buyer's time to terminate the deal based on its due diligence review findings. If the buyer terminates the transaction within the due diligence timeframe, the escrow deposit is commonly returned to the buyer. If the buyer has not terminated the agreement pursuant to the PSA contingencies, the escrow deposit becomes non-refundable and failure to complete the purchase will result in the escrow deposit funds to be transferred to the seller as a fee for failure to close.
The body and end are brought together in a seamer and held in place by the base plate and chuck, respectively. The base plate provides a sure footing for the can body during the seaming operation and the chuck fits snugly into the end (lid). The result is the countersink of the end sits inside the top of the can body just below the flange. The end curl protrudes slightly beyond the flange.
Compared with most other classes of natural compounds, alkaloids are characterized by a great structural diversity. There is no uniform classification. Initially, when knowledge of chemical structures was lacking, botanical classification of the source plants was relied on. This classification is now considered obsolete. More recent classifications are based on similarity of the carbon skeleton (e.g., indole-, isoquinoline-, and pyridine-like) or biochemical precursor (ornithine, lysine, tyrosine, tryptophan). However, they require compromises in borderline cases; for example, nicotine contains a pyridine fragment from nicotinamide and a pyrrolidine part from ornithine and therefore can be assigned to both classes. Alkaloids are often divided into the following major groups:
Sources: en.wikipedia.org
=== The Squibb Institute for Medical Research, Argentina === The Argentine government gave an exclusive license to Squibb to manufacture antibiotics in the country. To supplement the fermentation plant, Squibb constructed The Squibb Institute for Medical Research. This presented a truly unique opportunity for Ondetti, allowing him to work in one of the most advanced labs in Argentina with world-class scientists such as Dr. Deulofeu and Dr. Alfredo Sordelli. Another quirk about the Squibb laboratory was that Ondetti was not an official employee because he was a scholarship-research scientist, enabling him to focus on his thesis. Dr. Deulofeu was the head of chemistry at Squibb and his interests included alkaloid and carbohydrate chemistry. Ondetti reluctantly worked on carbohydrates for one year, after which Deulofeu offered him a job at Squibb. He refused, citing "I turned it down, because Deulofeu was an outstanding scientist, but he was very cold in the interaction with his collaborators". Realizing his mistake after one week of work at another company, he went back to Squibb and received a position there, resuming work on this thesis in 1957. Ondetti received his PhD from the University of Buenos Aires in 1960. As an employee as Squibb, Ondetti focused on alkaloid chemistry. Argentina's rich biodiversity allowed Squibb to screen many plants for unique and useful alkaloids. Any potential drug candidates were tested at The Squibb Research Institute in New Brunswick, New Jersey. The Squibb Research Institute in New Jersey was headed by Asger F.
=== Alcohol use disorder === Naltrexone has been best studied as a treatment for alcoholism, or alcohol use disorder (AUD). Naltrexone has been shown to decrease the quantity and frequency of alcohol consumption by reducing the release of dopamine, a neurotransmitter associated with the euphoria that often accompanies alcohol use. Studies comparing naltrexone to a placebo have shown a small but statistically significant decrease in relapse likelihood. Its overall benefit has been described as "modest". Acamprosate may be more effective for AUD management overall, while naltrexone may decrease the desire for alcohol to a greater extent. A method pioneered by scientist John David Sinclair (dubbed commercially the "Sinclair Method") in the 1980s advocates "pharmacological extinction" of problem drinking behavior by administering naltrexone alongside controlled alcohol consumption. In effect, he argues that naltrexone-induced opioid antagonism sufficiently disrupts reflexive reward mechanisms inherent in the consumption of alcohol and, given enough repetition, will dissociate positive associations formerly made with the consumption of alcohol. A 2001 review of eight studies of naltrexone treatment in the setting of AUD concluded that, "although all found benefits from naltrexone with the coping therapy, none of them found any significant benefit of naltrexone over placebo when combined with support for abstinence."
== Pharmacology == The half-life varies in around 8 hours at normal doses. Excretion is 65% through urine, mostly in unmetabolized form, and 28% via feces. Clearance is reduced in people with severe kidney disease. Delafloxacin is more active (lower MIC90) than other quinolones against Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). In contrast to most approved fluoroquinolones, which are zwitterionic, delafloxacin has an anionic character, which results in a 10-fold increase in delafloxacin accumulation in both bacteria and cells at acidic pH. This property is believed to confer to delafloxacin an advantage for the eradication of Staphylococcus aureus in acidic environments, including intracellular infections and biofilms. Given its anti-biofilm activity, delafloxacin is increasingly being considered as a treatment option for hardware-associated infections.
Sources: en.wikipedia.org
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.
Oxidation of the methionine residue to the sulfoxide is a frequently reported change, and it usually appears as an earlier-eluting peak in reversed-phase chromatography. Backbone hydrolysis products can also accumulate in aqueous solution.
Liquid chromatography coupled with mass spectrometry is the usual approach, because the observed molecular ion can be compared with a calculated mass of about 813.9 Da. Retention time alone does not establish identity.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.